Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

Proportion of patients with undetectable MRD by ctDNA, who, after discontinuation of anti-HER2 therapy, remain free from mBC progression over a two-year follow-up period. Anti-HER2 therapy could be reintroduced upon molecular progression.

Interventions

Perjeta 420 mg concentrate for solution for infusionType not reported

Phesgo 1200 mg/600 mg solution for injectionType not reported

Perjeta 420 mg concentrate for solution for infusionType not reported

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Perjeta 420 mg concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry record
Formulated product
Perjeta 420 mg concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry record

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

Perjeta 420 mg concentrate for solution for infusion
Named ingredient: pertuzumab
View registry record
Perjeta 420 mg concentrate for solution for infusion
Named ingredient: pertuzumab
View registry record

Eligibility Criteria

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients (men or women) should be older than 18 years of age
Patients must have signed a written informed consent form (ICF) prior to any trial specific procedures
Confirmed diagnosis of metastatic disease (Stage IV according to AJCC Staging – 8th edition) and histologically proven HER2+ mBC (according to ASCO-CAP guidelines)

Sponsors & Collaborators

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Otherlead

Study Sites (35)

Hospital Beata Maria Ana

Madrid, 28007, Spain

Lucia Sanz+34915044488 lucia.sanz@iobmadrid.com

ICO L'HOSPITALET HOSPITAL DURAN I REYNALS

Barcelona, 08908, Spain

Sonia Pernas+34932607733 spernas@iconcologia.net

Hospital Arnau De Vilanova De Valencia

Valencia, 46015, Spain

Antonio Llombart Cussac+34961976000

Central Study Contacts

Antonio Llombart

+34961976083 antonio.llombart@maj3.health

Study Design

Study Type: interventional
Phase: phase 2

Study Record Dates

First Submitted

July 14, 2026

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2026-526268-18-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-31 06:57:05 UTC

Documents

D1_Protocol 2026-526268-18-00

Anti-HER2 treatment Discontinuation Guided by ctDNA in Patients with HER2-Positive Metastatic Breast Cancer with Sustained Disease Control: PHENIX Trial

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (35)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (35)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations